In this study, our aim was to identify whether any member of the glypican family, glypican-1 to glypican-6, has a prognostic impact on the survival of breast cancer patients and could potentially act as therapeutic targets in the battle against the most common cancer in women. This evidence concerns the gene GPC1 and breast carcinoma.